Sydbanks årsrapport 2022
Selskabsmeddelelse nr. 03/2023
1. marts 2023
Sydbanks årsrapport 2022
Rekordresultat som følge af høj aktivitet og stigende renter
Sydbank-koncernens regnskab for 2022 viser et resultat før skat på 2.405 mio. kr. mod 1.764 mio. kr. i 2021. Stigningen på 641 mio. kr. kan primært henføres til en stigning i indtjeningen på 751 mio. kr. og et fald i basisomkostningerne på 137 mio. kr., modregnet effekten af lavere tilbageførsel af nedskrivninger på 316 mio. kr. Resultatet før skat forrenter den gennemsnitlige egenkapital med 18,9 pct. p.a.
Årets resultat udgør 1.901 mio. kr. mod 1.411 mio. kr. i 2021 og forrenter den gennemsnitlige egenkapital med 14,8 pct. efter skat. Ved indgangen til 2022 forventedes et resultat efter skat i intervallet 1.150-1.450 mio. kr.
Administrerende direktør Karen Frøsig siger om rekordresultatet:
- Det er meget glædeligt, at vi kan præstere det bedste resultat i bankens historie. Resultatfremgangen skyldes, at vi er lykkedes med at øge renteindtægterne betydeligt, samtidig med at vi har reduceret omkostningerne.
Karen Frøsig udtaler om udviklingen i renteindtægterne:
- Effekten af at Nationalbanken har hævet styringsrenten 4 gange i løbet af 2. halvår 2022 kan tydeligt ses på bankens nettorenteindtægter, der nu er på et markant højere niveau. Udviklingen i nettorenteindtægterne er væsentligt påvirket af stigningen i udlån samt en højere forrentning af bankens markante indlånsoverskud, der hidtil har været placeret til negativ forrentning.
Bestyrelsesformand Lars Mikkelgaard-Jensen siger:
- Det er meget tilfredsstillende, at rekordresultatet og bankens stærke kapitalforhold giver mulighed for et rekordhøjt udbytte på 16,77 kr. pr. aktie, svarende til 50 pct. af det opnåede resultat for 2022. Efter udbyttebetalingen er banken fortsat velkapitaliseret.
Forventninger til 2023
- Der forventes negativ vækst i dansk økonomi.
- Basisindtjeningen forventes at blive højere end i 2022.
- Basisomkostningerne forventes at blive højere end i 2022.
- Nedskrivningerne forventes at udgøre en mindre udgift.
- Omkostninger med engangskarakter forventes at udgøre i intervallet 50-60 mio. kr.
- Resultat efter skat forventes at være i intervallet 1.900-2.200 mio. kr.
- Forventningerne er forbundet med usikkerhed og afhænger af udviklingen på de finansielle markeder samt de makroøkonomiske forhold, der bl.a. kan påvirke niveauet for nedskrivninger.
Yderligere oplysninger
Bankdirektør Jørn Adam Møller, tlf. 74 37 20 30
Pressechef Susanne Ingemann Faber, tlf. 26 29 11 29
Vedhæftede filer
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release
VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi
Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa
Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release
BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe
Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release
First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann